| P50 | author | Fulvia Ceccarelli | Q86372522 |
| | Silvia Scriffignano | Q87844452 |
| | Ennio Lubrano | Q95989431 |
| | Cristiano Alessandri | Q55071174 |
| P2093 | author name string | Tania Colasanti | |
| | Cristiana Barbati | |
| | Fabio Massimo Perrotta | |
| | Antonia De Socio | |
| P2860 | cites work | Graphic representation of pain | Q95790597 |
| | Secukinumab for ankylosing spondylitis and psoriatic arthritis | Q28071474 |
| | A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index | Q28299001 |
| | High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage | Q31113598 |
| | Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis | Q33695718 |
| | Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 |
| | A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index | Q34307327 |
| | Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system | Q35554631 |
| | Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? | Q36633205 |
| | Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years | Q37350944 |
| | Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. | Q38203474 |
| | Wnt signaling in ankylosing spondylitis | Q38211262 |
| | Bone formation in axial spondyloarthritis. | Q38285600 |
| | The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial | Q39925539 |
| | Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. | Q41067642 |
| | Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis | Q41822526 |
| | Sclerostin and Dkk-1 in patients with ankylosing spondylitis | Q44776603 |
| | Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography | Q48008160 |
| | Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. | Q52879871 |
| | Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. | Q53212276 |
| | Ankylosing spondylitis | Q54165668 |
| | Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study | Q61633962 |
| | Can we stop progression of ankylosing spondylitis? | Q84377155 |
| | Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis | Q84819852 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| | biomarker | Q864574 |
| P304 | page(s) | 9101964 | |
| P577 | publication date | 2018-05-02 | |
| P1433 | published in | Journal of Immunology Research | Q26841936 |
| P1476 | title | Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study. | |
| P478 | volume | 2018 | |